Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions.
Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent. The difficulty of stem cell collection during thalidomide therapy is illustrated. The question of continuation of thalidomide after attainment of a plateau or remission is discussed and the management of neuropathy considered. Thalidomide, being a novel drug, presents a number of therapeutic issues that have yet to be resolved.
Desikan
R K
RK
Saint Vincent's Comprehensive Cancer Center, 325 W 15th St., New York, NY 10011, USA.
Jagannath
S
S
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D005938:Glucocorticoids; D013792:Thalidomide; D011241:Prednisone